Lowering LDL-C for cardiovascular disease
EAS Academy. Packard C. 04/24/17; 175496 Topic: Therapy
Disclosure(s): Honoraria from Roche, Sanofi, Regeneron, Amgen, Pfizer, MSD
Prof. Chris Packard
Prof. Chris Packard
Contributions
Abstract

This presentation was given as a plenary lecture at the EAS Congress in Prague, 2017, by Professor Chris Packard at the University of Glasgow, UK. In this lecture Professor Packard reviews the overwhelming evidence that LDL is the key causative factor for atherosclerosis – evidence obtained from experimental studies, epidemiology, genetics, pathophysiology and from clinical trials. He also takes this knowledge into the understanding of the mechanisms of the drugs shown to reduce CVD by reduction of LDL-Cholesterol.


 

Free access to the lecture will be open until June 30.

This presentation was given as a plenary lecture at the EAS Congress in Prague, 2017, by Professor Chris Packard at the University of Glasgow, UK. In this lecture Professor Packard reviews the overwhelming evidence that LDL is the key causative factor for atherosclerosis – evidence obtained from experimental studies, epidemiology, genetics, pathophysiology and from clinical trials. He also takes this knowledge into the understanding of the mechanisms of the drugs shown to reduce CVD by reduction of LDL-Cholesterol.


 

Free access to the lecture will be open until June 30.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies